Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in studies of small-animal models involving challenge by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 in treatment of nonhuman primates infected with variola virus or monkeypox virus was assessed. The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival.
Huggins
John
J
U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.
Goff
Arthur
A
Hensley
Lisa
L
Mucker
Eric
E
Shamblin
Josh
J
Wlazlowski
Carly
C
Johnson
Wendy
W
Chapman
Jennifer
J
Larsen
Tom
T
Twenhafel
Nancy
N
Karem
Kevin
K
Damon
Inger K
IK
Byrd
Chelsea M
CM
Bolken
Tove' C
TC
Jordan
Robert
R
Hruby
Dennis
D
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000627:therapeutic use*; D008252:Macaca fascicularis; D008297:Male; D045908:Mpox, Monkeypox / Q000517:prevention & control*; D012899:Smallpox / Q000517:prevention & control*; D010797:Phthalimides
D000998:Antiviral Agents; D001549:Benzamides; D054833:Isoindoles; C505045:tecovirimat; D010797:Phthalimides